Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Research & Development StartUps and SMEs BioPharmaceutical

Topas To Enter Clinic In 2018

Executive Summary

Timm Jessen, CEO of Topas Therapeutics, talks to Scrip's Lucie Ellis about his journey through the pharma and biotech sector and what lies ahead for his current company.

You may also be interested in...



Breath Therapeutics CEO On Aerosol Therapy Pipeline

Breath Therapeutics CEO Dr. Jens Stegemann chats to Scrip's Lucie Ellis about the company's pipeline of inhalation therapies.

Accessing Venture Debt From The EIB

Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.

In Vivo's 2024 Rising Leaders At A Glance

Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.

Table

View full table

Topics

Related Companies

Tags:
Research & Development StartUps and SMEs BioPharmaceutical
Latest Headlines

Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval

Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups

Investors Go Berserk For Viking, Putting It Top Of Q1 Winners

Sanofi Skates To Where The Puck Is With Immunology

See All
UsernamePublicRestriction

Register

SC100046

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By